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INTRODUCTION
Cytochrome P450s (CYPs) hold a major role in the hepatic metabolism of xenobiotics such as drugs, carcinogens and toxic agents. Metabolism can activate prodrugs to more pharmacologically active metabolites, inactivate pharmacologically active compounds or activate pre-carcinogens, thus triggering the formation of several tumors in humans (Gonzalez and Gelboin, 1994; Ingelman-Sundberg, 2004) . CYPs also catalyze the biotransformation of endogenous compounds, such as steroids and fatty acids (Guengerich, 2003; Spatzenegger and Jaeger, 1995) . Inhibition of CYP isoforms metabolizing clinically used drugs may lead to increased levels of a drugsubstrate in the body, and cause detrimental adverse effects, especially in situations when low therapeutic index drugs are used (Spatzenegger and Jaeger, 1995) .
Conversely, up-regulation of the critical enzymes may accelerate the metabolism of the drug-substrate, thus leading to reduced pharmacological outcome of the drug (Konstandi et al., 2005; Daskalopoulos et al., 2012) . It is therefore of importance, particularly in multi-drug therapies to be aware of the possibilities of drug-drug interactions, leading either to reduced/increased drug efficacy or severe toxicity and/or tumorigenesis (Gonzalez and Gelboin, 1994; Guengerich, 2003; Konstandi et al., 2004; Pelkonen et al., 2008) .
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indicated a critical role for hormones, such as the growth hormone (GH) (Waxman and O'Connor, 2006) , thyroid hormones (Takahashi et al., 2010) and insulin (Kim and Novak, 2007) in the regulation of various hepatic CYPs (Daskalopoulos et al., 2012) .
Diabetic rats display increased hepatic CYP2A1, CYP2C6/7, CYP2E1, CYP3A2 and CYP4A3 expression, which can be restored to normal levels by insulin administration (Shimojo et al., 1993) . Insulin exerts many of its effects via the PI3K/Akt signaling pathway, which regulates the expression of several genes, including various CYP isoforms (Kim and Novak, 2007) . Among upstream signaling factors regulating the release of insulin in response to increased plasma glucose levels, dopamine holds a significant role: stimulation of D 2 -dopaminergic receptors in the pancreatic β -cells, suppresses insulin release (Rubi et al., 2005) . In accordance with this and other earlier studies, we have shown that blockade of D 2 -dopaminergic receptors stimulated insulin release and markedly down-regulated CYP2E1 (Konstandi et al., 2008) . It is possible that in this regulation, the insulin/PI3K/Akt signaling pathway holds a determinant role (Woodcroft et al., 2002) .
A broad spectrum of drugs prescribed for a variety of disease states including schizophrenia, bipolar disorder, depression and Parkinson's disease; exert their effects mainly via D 2 -dopaminergic receptors, and the related signaling pathways (Beaulieu and Gainetdinov, 2011) . Given its central role in the regulation of insulin release, it is conceivable that drugs acting via this pathway could alter the expression of various drug metabolizing CYP enzymes, thus affecting the pharmacodynamics and toxicity of drug-substrates during pharmacotherapy (Gonzalez and Yu, 2006) .
The aim of this study was to assess the role of the D 2 -dopaminergic receptor linked signaling pathways in the regulation of the cytochromes CYP3A, CYP2C and
6 sulpiride (Konstandi et al., 2008) , a typical antipsychotic drug used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder (Maitre et al., 1994) . The direct effect of sulpiride on hepatocytes was also assessed in vitro using primary hepatocyte cultures. Blockade of the D 2 -dopaminergic signaling pathways caused a strong reduction in the expression of cytochromes CYP3A, CYP2C
and CYP2D. Given the fact that the vast majority of the prescribed drugs are metabolized by these CYPs, their down-regulation would lead to strongly increased blood levels of drug-substrates during multi-drug therapy and drug-drug interactions with potentially detrimental side effects.
Isolation of microsomes
Microsomal fractions were prepared from liver samples which were homogenized in ice-cold homogenization buffer (0.15 M KCl, 10 mM K 2 EDTA, 1mM dithiothreitol, pH 7.4). The homogenates were centrifuged at 14,075 g (4 ο C) for 20 min. The upper phase was transferred into new vials and was centrifuged for 60 min at 96,552 g (4 ο C). The microsomal pellet was re-suspended in ice-cold homogenization buffer, homogenized and centrifuged for 45 min at 96,552 g (4 ο C).
The washed microsomal pellet was re-suspended in ice-cold storage buffer (K 2 HPO4/KH 2 PO4, pH 7.4, 1 mM K 2 EDTA, 0.1 mM dithiothreitol, 20% glycerol) and stored at -80 ο C until assayed (Lang et al., 1981) .
Primary hepatocyte cultures
Primary hepatocytes were isolated and used in cultures according to the method of Klaunig et al. (Klaunig et al., 1981) . In brief, primary hepatocytes were isolated from rats weighing 250-300 g using a two-step collagenase perfusion method. 
Enzyme activity
Bufuralol 1′-hydroxylation
Bufuralol 1′-hydroxylation reflects the cytochrome CYP2D activity (Matsunaga et al., 1990) . Liver microsomal protein (40 μ g) was pre-incubated at 37°C
for 5 min in a 200 μ l reaction mixture containing potassium phosphate (100 mM, pH 7.4) in the presence of 50 μ M bufuralol substrate. The reaction was initiated with NADPH (0.5 mM) at 37 o C and lasted 7.5 min. It was terminated using 20 μ l of perchloric acid 60%. After centrifugation at 14,075 g for 10 min, the concentration of 1'-hydroxy-bufuralol (main metabolite of bufuralol) was determined in the supernatant (100 μ l) by HPLC with a fluoroscence detector at 252 and 302 nm. A reversed phase Luna C 18 column (5 μ m, 150 x 3 mm) was used. The mobile phase contained a mixture of 30% acetonitrile (ACN) and 70% perchlorate buffer 20 mM (pH 2.5) and the sample was eluted at a flow rate of 1 ml/min for 15 min.
The positive control of the bufuralol1΄-hydroxylation took place using the following recombinant CYPs (rCYP), the rat CYP2D1 and CYP2D2 + P450
Reductase Supersomes (BD Biosciences-Gentest 
Testosterone hydroxylation
Cytochromes CYP3A1/2, CYP2C11 and CYP2A1 catalyze testosterone hydroxylation in the rat liver. The activities studied were the CYP3A1/2 dependent 6β-testosterone hydroxylation and the CYP2C11-dependent 2α-and 16α-testosterone hydroxylation (Murray et al., 2001) . Briefly, liver microsomal proteins (1 mg) were incubated at 37°C for 7.5 min in 500 μ l of a mixture containing potassium phosphate 
Western blot analysis
Immunoblot analysis of the cytochrome CYPs, STAT5b and FOXO1 apoprotein levels was carried out using microsomes and nuclear extracts or cytosol of liver samples, respectively. For the preparation of the nuclear extracts and cytosol the This article has not been copyedited and formatted. The final version may differ from this version. Immunoblotting with GAPDH or β -actin (Santa Cruz Biotechnology) and anti-mouse IgG horseradish peroxidase conjugated secondary antibody, were used as loading control.
Quantitative real-time PCR
For the isolation of total RNA from liver tissue and primary hepatocytes, the TRIzol reagent was used (Invitrogen) following the manufacturer's protocol. The concentration of total RNA was determined with a spectrophotometric method.
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Quantitative real-time reverse transcriptase PCR (qPCR) was performed with cDNA generated from 1 μ g total RNA with a SuperScript II reverse transcriptase kit (Invitrogen). The sequences for the forward and reverse gene-specific primers used are shown in the Table 1 . SYBR Green PCR master mix (Applied Biosystems, Warrington, UK) was used for the real-time reactions, which were carried out using the Thermal Cycler Real-Time Detection System C1000 (BioRad, Italy). Relative mRNA expression levels were normalized to β -actin (QuantiTect Primer Assay, Qiagen) and values were quantified using the comparative threshold cycle method.
Hormonal determinations
Serum corticosterone concentrations were measured using the Corticosterone RIA kit (Coat-A-Count kit, Diagnostic Products Corporation, USA). The detection limit was approximately 5.7 ng/ml and the intra-assay coefficient of variation (CV) was 4.0%. The GH serum levels were assessed with the rat growth hormone RIA kit (Millipore, MA, USA). The detection limit was 0.5 ng/ml and the intra-assay coefficient of variation was 10%. Prolactin (PRL) serum levels were measured with the rat prolactin RIA kit (MP Biomedicals Europe, France) and the detection limit was 0.5 ng/ml. Serum thyroid hormone concentrations were measured with the Dynatest T3, Dynatest T4 and Dynatest TSH kits (Brahms, Germany). The normal ranges were 80-200 ng/dl (Dynatest T3), 4.5-12 μ g/dl (Dynatest T4) and 0.4-4 mg/ml (Dynatest TSH), respectively. The insulin levels were measured using an ELISA kit (Mercodia Rat ELISA kit for insulin, Uppsala, Sweden). The detection limit was 3.3 ng/ml and the intra-assay coefficient of variation was 3.1%. The blood glucose levels were measured with a commercially available kit (Merck, Germany) using the technique of glucose oxidase (Trinder, 1969) .
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Statistical analysis
Data were analysed using the one-way analysis of variance (ANOVA)
followed by multiple comparisons with Bonferonni's and Tuckey's list honest significant difference methods and is presented as the mean ± SE. In all cases, probability value of p≤0.05 was considered as significant.
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RESULTS
Involvement of D 2 -dopaminergic receptor-linked pathways in CYP3A regulation
In vivo administration of the D 2 -dopaminergic receptor antagonist, SULP, resulted in the down-regulation of the hepatic CYP3A1/2 expression. Both the CYP3A-dependent 6β-testosterone hydroxylation, CYP3A1/2 apoprotein and mRNA levels were detected at markedly lower levels in SULP-treated rats compared to controls (Fig. 1) . The highly selective D 2 -dopaminergic antagonist L-741,626 also repressed CYP3A1/2 expression at mRNA, apoprotein and activity level (Fig. 1) .
In contrast, in vitro experiments using primary hepatocyte cultures demonstrated that D 2 -dopaminergic receptor blockade with SULP markedly increased CYP3A1 and CYP3A2 mRNA levels (Fig 2A) . This increase was not mediated by the JNK-, cAMP/PKA-, or PI3K-related pathways, as neither the JNK inhibitor, SP600125, the PKA inhibitor, H89,or the PI3K inhibitor, Wortmannin (WORT), prevented it ( Fig. 2A) . Interestingly, incubation of primary hepatocytes with insulin (INS) strongly suppressed CYP3A1/2, whereas this suppressive effect was completely reversed by WORT (Fig. 2B) .
Involvement of D 2 -dopaminergic receptor-linked pathways in CYP2C regulation
In vivo administration of SULP markedly suppressed CYP2C11 expression in the liver of rats, as assessed at enzyme activity level (2α-and 16α-testosterone hydroxylation), as well as at apoprotein and mRNA levels (Fig 3) . L-741,626 also repressed CYP2C11 expression at mRNA, apoprotein and 2α-and 16α-testosterone hydroxylation level (Fig. 3) This article has not been copyedited and formatted. The final version may differ from this version. However, SULP significantly increased CYP2C11 expression in vitro (Fig   2A) , an effect that was not prevented by SP600125, H89 or WORT ( Fig. 2A) . And, as in the case of CYP3A, treatment of primary hepatocytes with INS markedly decreased CYP2C11 mRNA transcripts, an effect completely blocked by WORT (Fig. 2B) .
Involvement of D 2 -dopaminergic receptor-linked pathways in CYP2D regulation
Blockade of D 2 -dopaminergic receptors with SULP markedly decreased the CYP2D-dependent 1΄-bufuralol hydroxylation, as well as the CYP2D1 mRNA transcripts and apoprotein, compared to controls (Fig 4) . L-741,626 also repressed CYP2D1/2 expression (Fig. 4) Similarly to the CYP3A and CYP2C, treatment of primary hepatocytes with SULP resulted in an up-regulation of CYP2D1 and CYP2D2 ( Fig. 2A ) and this upregulation was not prevented by neither SP600125, H89 or WORT ( Fig. 2A) . In contrast, INS strongly suppressed CYP2D1 and CYP2D2, an effect completely blocked by WORT (Fig. 2B ).
Positive and negative control of CYP-dependent activities
Incubation of liver microsomes with Ketoconazole markedly suppressed the CYP3A-catalyzed 6β-testosterone hydroxylation compared to that of microsomes incubated with the vehicle (Supplemental Figure 1A) . 2α-and 16α-testosterone hydroxylation was also significantly suppressed by Sulfaphenazole (Supplemental Figure 1B and 1C) . In contrast, incubation of liver microsomes with SULP did not modify these activities (Supplemental Figure 1A-1C ).
This article has not been copyedited and formatted. The final version may differ from this version. Incubation of rCYP3A1 with SULP increased the 6β-testosterone hydroxylation, whereas SULP had no effect on rCYP3A2-catalyzed activity (Supplemental Figure 1D) . Interestingly, the D 2 -antagonist markedly repressed the rCYP2C11-catalyzed 2α-and 16α-testosterone hydroxylation (Supplemental Figure   1E and 1F), whereas SULP had no effect on the rCYP2D1 and rCYP2D2-catalyzed bufuralol 1΄-hydroxylation (Supplemental Figure 1G and 1H) .
Assessment of D 2 -dopaminergic receptor blockade on hormonal state
Treatment of rats with SULP strongly suppressed plasma GH, triiodothyronine (T3), thyroxin (T4) and corticosterone concentrations (Table 2 ). In contrast, SULP markedly increased plasma prolactin levels (PRL, Table 2 ). It is of importance to this study that the drug also increased plasma insulin levels, followed by a reduced plasma glucose concentration (Table 2) .
Assessment of D 2 -dopaminergic receptor-mediated effect on PI3K/Akt/FOXO1 pathway
The D 2 -dopaminergic antagonist SULP markedly increased the phosphorylation of Akt in the liver of rats (Fig. 5A) . Moreover, the phosphorylation of p70S6K, a down-stream element in the PI3K/Akt pathway, was also strongly increased following SULP treatment (Fig. 5A) . Interestingly, SULP strongly decreased the levels of phosphorylated FOXO1 in the nucleus of hepatocytes (Fig.   5B ), whereas they were markedly increased in the cytosol (Fig. 5C ). It should be also noted that SULP up-regulated eNOS and iNOS (fold induction, mean ± SE, Control
This article has not been copyedited and formatted. The final version may differ from this version. vsSULP, 1.0 ± 0.13 vs 1.8 ± 0.22, n=10, p<0.01, iNOS and 1.0 ± 0.12 vs 2.0 ± 0.14, n=10, p<0.01, eNOS).
L-741,626 had also similar effects with SULP on the PI3K/Akt/FOXO1signal transduction pathway (Fig. 6A-6C) .
Assessment of the D 2 -dopaminergic receptor-mediated effect on STAT5b activation
It is well established that growth hormone (GH) and the GH-pulse activated markedly reduced STAT5b activation in the nucleus and cytoplasm compared to controls ( Fig. 6B and 6C ).
D 2 -receptor mediated effect on nuclear transcription factors involved in CYP regulation
CAR, PXR, RXRα and HNF1α mRNA levels were detected at markedly lower levels in the liver of SULP-and L-741,626-treated rats compared to controls (Fig. 7A-7D ). No significant change though, was observed in the hepatic HNF4α expression following SULP, whereas L-741,626 suppressed it (Fig 7E) . CREB phosphorylation, a down-stream element in the cAMP/PKA signaling pathway and JNK phosphorylation were also suppressed by both SULP and L-741,626 ( Figure 5A and 6A).
This article has not been copyedited and formatted. The final version may differ from this version. In vitro experiment using primary hepatocyte cultures showed that treatment of the cells with SULP increased CAR mRNA transcripts. This increase is profoundly mediated by the JNK, cAMP/PKA and PI3K-linked signaling pathways as it was prevented by the corresponding inhibitors, SP600125, H89 and WORT (Fig. 7A ).
RXRα mRNA was also increased following treatment of the hepatocytes with SULP, and this increase was mainly mediated by the JNK-linked pathway (Fig. 7C) . PXR, HNF1α and HNF4α mRNA expressions were not affected by a direct exposure of hepatocytes to SULP (Fig. 7B, 7D and 7E ).
This article has not been copyedited and formatted. The final version may differ from this version. interest to note also that in vitro experiments using recombinant CYP2C11 revealed a direct down-regulating effect of the drug on this cytochrome.
The role of insulin in the D 2 -receptor mediated CYP down-regulation appears to be crucial. This hypothesis is based on the notion that insulin release, which holds a negative regulatory control on several CYPs (Yoshida et al., 1996; Woodcroft and Novak, 1997; Woodcroft and Novak, 1999 and inhibits its activity, whereas JNK increases FOXO activity by promoting its import in the nucleus (Brunet et al., 1999; Essers et al., 2004; Wang et al., 2005) , we This article has not been copyedited and formatted. The final version may differ from this version. hypothesize that the SULP-induced down-regulating effect on CYPs involving FOXO1 is the outcome of the drug's combined effect on both, Akt and JNK signaling pathways.
FOXO1 is a part of a complex cross-talking mechanism that also includes the nuclear receptors constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) (Kodama et al., 2004) . These nuclear receptors, along with the retinoic X receptor (RXR), the hepatocyte nuclear factor 1α (HNF1α) and 4α (HNF4α) (Liddle et al., 1998; Wiwi and Waxman, 2004) -are known to regulate the most important hepatic CYP genes, including members of the CYP3A and CYP2C subfamilies (Dvorak and Pavek, 2010) . Importantly, SULP has also down-regulated the expression of CAR, PXR, RXRα and HNF1α, indicating that the drug's suppressive effect on CYP3A1/2 and CYP2C11 is potentially mediated by these nuclear factors.
Moreover, SULP up-regulated both eNOS and iNOS in the liver. It is well It is also possible that both GH and PRL, play a role in the down-regulation of these CYPs by SULP. SULP reduced plasma GH levels, followed by reduced phosphorylation of STAT5b: the major GH pulse-activated transcription factor, which psychotic patients receiving drug therapy, usually including D 2 -antagonists (Rassidakis et al., 1973; Rice, 1979; Craig and Lin, 1981; Mortensen, 1989) 
